Enliven Therapeutics Stock (NASDAQ:ELVN)


Chart

Previous Close

$20.32

52W Range

$13.30 - $30.03

50D Avg

$19.66

200D Avg

$20.28

Market Cap

$1.26B

Avg Vol (3M)

$466.55K

Beta

1.02

Div Yield

-

ELVN Company Profile


Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

62

IPO Date

Mar 12, 2020

Website

ELVN Performance


Peer Comparison


TickerCompany
IRONDisc Medicine, Inc.
OBIOOrchestra BioMed Holdings, Inc.
FENCFennec Pharmaceuticals Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks